论文部分内容阅读
目的:探究甘精胰岛素联合瑞格列奈在治疗2型糖尿病的临床疗效,结合具体情况,探究其应用价值。方法:在本次研究中选择2014年1月-2016年4月我院收治的47例2型糖尿病患者为研究对象,随机分为对照组和治疗组,分别给予常规性治疗和甘精胰岛素联合瑞格列奈进行治疗,对治疗效果进行分析。结果:对照组有效人数15例,明显低于治疗组21例有效人数,治疗组总有效率87.5%,高于对照组的65.2%,治疗组的治疗优势更明显,具有统计学差异(p<0.05)。治疗组和对照组治疗前的空腹血糖和餐后2h血糖无差异(p>0.05),治疗组治疗后的空腹血糖和餐后2h血糖指标趋于正常,比较结果差异显著,具有统计学意义(p<0.05)。结论:对2型糖尿病患者应用甘精胰岛素联合瑞格列奈进行治疗,其优势明显,能达到降低血糖的目的,值得临床推广应用。
Objective: To investigate the clinical efficacy of insulin glargine combined with repaglinide in the treatment of type 2 diabetes mellitus, and to explore its application value according to the specific conditions. Methods: Forty-seven patients with type 2 diabetes who were admitted to our hospital from January 2014 to April 2016 were selected as the study subjects and randomly divided into control group and treatment group. Patients were given conventional therapy and insulin glargine Repaglinide for treatment, the treatment effect analysis. Results: The effective number of the control group was 15 cases, which was significantly lower than that of the 21 cases in the treatment group. The total effective rate was 87.5% in the treatment group, which was higher than that in the control group (65.2%). The treatment advantage was more obvious in the treatment group with statistical significance (p < 0.05). The fasting blood glucose and postprandial 2h blood glucose of the treatment group and the control group were no difference (p> 0.05). The fasting blood glucose and postprandial 2h blood glucose index of the treatment group tended to be normal, the difference was significant, with statistical significance p <0.05). Conclusion: The application of insulin glargine combined with repaglinide in type 2 diabetic patients has obvious advantages and can achieve the goal of lowering blood glucose, which is worthy of clinical application.